Novel selective compounds for the investigation of imidazoline receptors

Alan L. Hudson, R. Gough, R. Tyacke, L. Lione, M. Lalies, J. Lewis, S. Husbands, P. Knight, F. Murray, P. Hutson, D. J. Nutt

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Over several years our group has sought to synthesize and identify selective ligands for imidazoline (I) receptors, in particular the I2 binding site. As a consequence, [3H]2-(2-benzofuranyl)-2-imidazoline (2BFI) has proved extremely useful for binding and autoradiographic studies. More recently we have synthesized a BU series of compounds and examined these for their affinities for both I1 and I2 binding sites. BU224 (2-(4,5-dihydroimidaz-2-yl)-quinoline) shows high affinity for I2 receptors with a K(i) of 2.1 nM. BU226 (2-(4,5-dihydroimidaz-2-yl)-isoquinoline) demonstrated slightly higher affinity (K(i) 1.4 nM) for I2 receptors, but overall BU224 displayed greater selectivity for I2 over I1 receptors (832-fold) than BU226 (380-fold). Both compounds showed low (μM) affinity for α2-adrenoceptors. Given BU224's ability to cross the blood brain barrier, we predict that its in vivo effects are likely to be mediated via I2 receptors. Brain dialysis revealed BU224 to dose dependently (0-20 mg/kg ip) elevate basal noradrenaline in rat frontal cortex and basal dopamine in striatum. In a rat model of opiate withdrawal, behavioral studies showed that BU224 (10 mg/kg, sc) was able to reduce acute weight loss and diarrhea, but not the number of wet dog shakes associated with the withdrawal syndrome.

Original languageEnglish
Pages (from-to)81-91
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume881
Issue number1
DOIs
Publication statusPublished - 1 Jun 1999

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Hudson, A. L., Gough, R., Tyacke, R., Lione, L., Lalies, M., Lewis, J., ... Nutt, D. J. (1999). Novel selective compounds for the investigation of imidazoline receptors. Annals of the New York Academy of Sciences, 881(1), 81-91. https://doi.org/10.1111/j.1749-6632.1999.tb09344.x

Novel selective compounds for the investigation of imidazoline receptors. / Hudson, Alan L.; Gough, R.; Tyacke, R.; Lione, L.; Lalies, M.; Lewis, J.; Husbands, S.; Knight, P.; Murray, F.; Hutson, P.; Nutt, D. J.

In: Annals of the New York Academy of Sciences, Vol. 881, No. 1, 01.06.1999, p. 81-91.

Research output: Contribution to journalArticle

Hudson, AL, Gough, R, Tyacke, R, Lione, L, Lalies, M, Lewis, J, Husbands, S, Knight, P, Murray, F, Hutson, P & Nutt, DJ 1999, 'Novel selective compounds for the investigation of imidazoline receptors', Annals of the New York Academy of Sciences, vol. 881, no. 1, pp. 81-91. https://doi.org/10.1111/j.1749-6632.1999.tb09344.x
Hudson, Alan L. ; Gough, R. ; Tyacke, R. ; Lione, L. ; Lalies, M. ; Lewis, J. ; Husbands, S. ; Knight, P. ; Murray, F. ; Hutson, P. ; Nutt, D. J. / Novel selective compounds for the investigation of imidazoline receptors. In: Annals of the New York Academy of Sciences. 1999 ; Vol. 881, No. 1. pp. 81-91.
@article{2701183c0ccc4431a90cd61ebcd0bc3a,
title = "Novel selective compounds for the investigation of imidazoline receptors",
abstract = "Over several years our group has sought to synthesize and identify selective ligands for imidazoline (I) receptors, in particular the I2 binding site. As a consequence, [3H]2-(2-benzofuranyl)-2-imidazoline (2BFI) has proved extremely useful for binding and autoradiographic studies. More recently we have synthesized a BU series of compounds and examined these for their affinities for both I1 and I2 binding sites. BU224 (2-(4,5-dihydroimidaz-2-yl)-quinoline) shows high affinity for I2 receptors with a K(i) of 2.1 nM. BU226 (2-(4,5-dihydroimidaz-2-yl)-isoquinoline) demonstrated slightly higher affinity (K(i) 1.4 nM) for I2 receptors, but overall BU224 displayed greater selectivity for I2 over I1 receptors (832-fold) than BU226 (380-fold). Both compounds showed low (μM) affinity for α2-adrenoceptors. Given BU224's ability to cross the blood brain barrier, we predict that its in vivo effects are likely to be mediated via I2 receptors. Brain dialysis revealed BU224 to dose dependently (0-20 mg/kg ip) elevate basal noradrenaline in rat frontal cortex and basal dopamine in striatum. In a rat model of opiate withdrawal, behavioral studies showed that BU224 (10 mg/kg, sc) was able to reduce acute weight loss and diarrhea, but not the number of wet dog shakes associated with the withdrawal syndrome.",
author = "Hudson, {Alan L.} and R. Gough and R. Tyacke and L. Lione and M. Lalies and J. Lewis and S. Husbands and P. Knight and F. Murray and P. Hutson and Nutt, {D. J.}",
year = "1999",
month = "6",
day = "1",
doi = "10.1111/j.1749-6632.1999.tb09344.x",
language = "English",
volume = "881",
pages = "81--91",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Novel selective compounds for the investigation of imidazoline receptors

AU - Hudson, Alan L.

AU - Gough, R.

AU - Tyacke, R.

AU - Lione, L.

AU - Lalies, M.

AU - Lewis, J.

AU - Husbands, S.

AU - Knight, P.

AU - Murray, F.

AU - Hutson, P.

AU - Nutt, D. J.

PY - 1999/6/1

Y1 - 1999/6/1

N2 - Over several years our group has sought to synthesize and identify selective ligands for imidazoline (I) receptors, in particular the I2 binding site. As a consequence, [3H]2-(2-benzofuranyl)-2-imidazoline (2BFI) has proved extremely useful for binding and autoradiographic studies. More recently we have synthesized a BU series of compounds and examined these for their affinities for both I1 and I2 binding sites. BU224 (2-(4,5-dihydroimidaz-2-yl)-quinoline) shows high affinity for I2 receptors with a K(i) of 2.1 nM. BU226 (2-(4,5-dihydroimidaz-2-yl)-isoquinoline) demonstrated slightly higher affinity (K(i) 1.4 nM) for I2 receptors, but overall BU224 displayed greater selectivity for I2 over I1 receptors (832-fold) than BU226 (380-fold). Both compounds showed low (μM) affinity for α2-adrenoceptors. Given BU224's ability to cross the blood brain barrier, we predict that its in vivo effects are likely to be mediated via I2 receptors. Brain dialysis revealed BU224 to dose dependently (0-20 mg/kg ip) elevate basal noradrenaline in rat frontal cortex and basal dopamine in striatum. In a rat model of opiate withdrawal, behavioral studies showed that BU224 (10 mg/kg, sc) was able to reduce acute weight loss and diarrhea, but not the number of wet dog shakes associated with the withdrawal syndrome.

AB - Over several years our group has sought to synthesize and identify selective ligands for imidazoline (I) receptors, in particular the I2 binding site. As a consequence, [3H]2-(2-benzofuranyl)-2-imidazoline (2BFI) has proved extremely useful for binding and autoradiographic studies. More recently we have synthesized a BU series of compounds and examined these for their affinities for both I1 and I2 binding sites. BU224 (2-(4,5-dihydroimidaz-2-yl)-quinoline) shows high affinity for I2 receptors with a K(i) of 2.1 nM. BU226 (2-(4,5-dihydroimidaz-2-yl)-isoquinoline) demonstrated slightly higher affinity (K(i) 1.4 nM) for I2 receptors, but overall BU224 displayed greater selectivity for I2 over I1 receptors (832-fold) than BU226 (380-fold). Both compounds showed low (μM) affinity for α2-adrenoceptors. Given BU224's ability to cross the blood brain barrier, we predict that its in vivo effects are likely to be mediated via I2 receptors. Brain dialysis revealed BU224 to dose dependently (0-20 mg/kg ip) elevate basal noradrenaline in rat frontal cortex and basal dopamine in striatum. In a rat model of opiate withdrawal, behavioral studies showed that BU224 (10 mg/kg, sc) was able to reduce acute weight loss and diarrhea, but not the number of wet dog shakes associated with the withdrawal syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0032799471&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1999.tb09344.x

DO - 10.1111/j.1749-6632.1999.tb09344.x

M3 - Article

VL - 881

SP - 81

EP - 91

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -